Delivering a high degree of sensitivity for HCC detection

Designed for accurate early-stage detection in real-world settings

The OncoguardTM Liver test was designed to deliver a high level of accuracy with enhanced sensitivity for detection of early-stage HCC.1

Chris-Conroy-Photography-2450-small

 

At 87% specificity, the OncoguardTM Liver test demonstrates:

82%sensitivity forearly-stage HCC
94%sensitivity forlate-stage HCC

Validation of the test demonstrated high performance compared with:

AFP40%sensitivity forearly-stage AFP1
vs.
82%sensitivity forearly-stage HCC1
doctor interacting with patient

Survival rates for patients with HCC are improved with early-stage detection

Localized stage

60-70%

Five-year survival rate for those who are diagnosed at an early stage and undergo curative therapy

Regional stage
Distant stage

3-12%

Five-year survival rate for those diagnosed at late stage2

Asset 12

The strong performance of the OncoguardTM Liver test combined with easy-to-interpret results may enable early-stage HCC detection—a fundamental step toward improving outcomes for patients.1

Learn more about the Scientific Rigor behind the OncoguardTM Liver test.

Learn more

References: 1. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021), doi: https:// doi.org/10.1016/j.cgh.2021.08.010 2. Liver cancer survival rates. American Cancer Society. Revised January 29, 2021. Accessed March 23, 2021. https://www.cancer.org/cancer/liver-cancer/detection-diagnosis-staging/survival-rates.html